Leflunomide is a commonly used drug for the treatment of rheumatoid immune diseases, discontinuation of the drug needs to be decided according to the condition itself, the drug has no adverse effects. Leflunomide belongs to the immunosuppressant, suitable for adults with rheumatoid arthritis, and has the effect of improving the condition. If the condition is under control after treatment, it can be discontinued under the guidance of a medical professional. Leflunomide should also be discontinued if more serious adverse reactions such as severe impairment of liver function and decreased blood counts occur. Women of childbearing age who need to become pregnant should stop taking Leflunomide earlier. Common adverse reactions include diarrhea, pruritus, reversible elevation of liver enzymes (ALT and AST), alopecia, and rash. It is contraindicated in persons who are hypersensitive to the product and its metabolites and in patients with severe liver damage. Note that ALT and leukocytes should be checked regularly during the initial phase of drug administration, and should be used with caution in patients with severe hepatic impairment and definitively positive hepatitis B or C serology. If patients undergoing leflunomide treatment want to stop the drug, it is recommended to go to the rheumatology and immunology department of the hospital, whether to stop the drug after a comprehensive assessment by a specialist.